H. pylori rescue eradication therapy with lascufloxacin, amoxicillin, and vonoprazan

Single-arm prospective interventional study of Helicobacter pylori eradication rescue therapy with lascufloxacin, amoxicillin, and vonoprazan 7day

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200154

Enrollment

Registered

2020-10-15

Start date

2020-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection Helicobacter pylori

Interventions

Vonoprazan 20mg bid (40mg/day), amoxicillin 750mg bid (1500mg/day), and lascufloxacin 75mg sid (75mg/day) 7days

Helicobacter pylori eradication therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients diagnosed with Helicobacter pylori infection (2)Patients with clarithromycin and metronidazole resistant H. pylori infection or patients who failed eradication by both triple therapy with clarithromycin and amoxicillin and triple therapy with metronidazole and amoxicillin.

Exclusion criteria

Exclusion criteria: (1)Past history of allergy for vonoprazan, amoxicillin, or lascufloxacin. (2)Patients with infectious mononucleosis. (3)Patients taking atazanavir or rilpivirine. (4)Pregnancy. (5)Lactation. (6)Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. (7)Patients who are disqualified for the study by physicians.

Design outcomes

Primary

Measure	Time frame
Eradication rate (FAS)	—

Secondary

Measure	Time frame
(1) Eradication rate (PPS) (2) Safety	—

Contacts

Public ContactSoichiro Sue

Yokohama City University Hospital

ssue@yokohama-cu.ac.jp+81-457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026